biotech · Parkinson Disease · Amyotrophic Lateral Sclerosis · DNLI
Denali Therapeutics
NovaPharmaNews editorial coverage mentioning Denali Therapeutics — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 161 Oyster Point Blvd, South San Francisco, California 94080, US
- Founded
- 2015
- Employees
- 567
- Programs
- 23
- Drugs
- 10
- Patents
- 42
News & analysis
NovaPharmaNews articles mentioning Denali Therapeutics — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Denali Therapeutics — regulatory, clinical, and market analysis.
Biogen and Denali's Parkinson's Drug Trial: What Went Wrong?
Biogen and Denali's recent trial for a Parkinson's drug has not met expectations, raising questions about future strategies and investments in this space.
Biogen and Denali Abandon Parkinson's Drug After Study Setback
Biogen and Denali have decided to discontinue their drug for non-genetic Parkinson's disease following disappointing mid-stage study results. This article explores the implications for the pharmaceutical landscape.